Immix Biopharma is trading 10.81% lower at $10.23 after pricing a $125 million underwritten offering, creating dilution pressure.
- The company will issue 11,363,637 shares at $11.00 each.
- Proceeds are intended to support NXC-201 development, working capital, and general corporate purposes.
- Closing is expected around September 30, following the September 29, 2026 pricing, subject to customary conditions.